Intellia Therapeutics, Inc. (NTLA)
NASDAQ: NTLA · Real-Time Price · USD
8.55
+0.43 (5.30%)
At close: May 12, 2025, 4:00 PM
8.66
+0.11 (1.29%)
After-hours: May 12, 2025, 7:54 PM EDT
Intellia Therapeutics Stock Forecast
Stock Price Forecast
The 20 analysts with 12-month price forecasts for Intellia Therapeutics stock have an average target of 38.6, with a low estimate of 10 and a high estimate of 90. The average target predicts an increase of 351.46% from the current stock price of 8.55.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Intellia Therapeutics stock from 20 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
---|---|---|---|---|---|---|
Strong Buy | 5 | 5 | 5 | 6 | 6 | 7 |
Buy | 7 | 7 | 6 | 6 | 7 | 7 |
Hold | 5 | 6 | 6 | 6 | 6 | 6 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 17 | 18 | 17 | 18 | 19 | 20 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
Guggenheim | Guggenheim | Strong Buy Maintains $55 → $45 | Strong Buy | Maintains | $55 → $45 | +426.32% | May 12, 2025 |
Citigroup | Citigroup | Hold Maintains $14 → $10 | Hold | Maintains | $14 → $10 | +16.96% | May 9, 2025 |
Chardan Capital | Chardan Capital | Strong Buy Maintains $68 | Strong Buy | Maintains | $68 | +695.32% | May 9, 2025 |
Wolfe Research | Wolfe Research | Hold → Buy Upgrades $21 | Hold → Buy | Upgrades | $21 | +145.61% | Apr 21, 2025 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $30 | Strong Buy | Initiates | $30 | +250.88% | Mar 5, 2025 |
Financial Forecast
Revenue This Year
55.62M
from 57.88M
Decreased by -3.90%
Revenue Next Year
50.46M
from 55.62M
Decreased by -9.28%
EPS This Year
-4.81
from -5.25
EPS Next Year
-4.65
from -4.81
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | 220.5M | 105.0M | 4.0B | ||
Avg | 55.6M | 50.5M | 385.2M | ||
Low | n/a | 6.9M | 3.6M |
Revenue Growth
Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | 281.0% | 88.8% | 7,780.1% | ||
Avg | -3.9% | -9.3% | 663.5% | ||
Low | - | -87.7% | -92.9% |
EPS Forecast
EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | -3.35 | -3.03 | -3.06 | ||
Avg | -4.81 | -4.65 | -4.10 | ||
Low | -5.60 | -5.60 | -5.08 |
EPS Growth
EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | - | - | - | ||
Avg | - | - | - | ||
Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.